Tirzepatide dosage: the labeled dose ranges and titration schedules documented in the SURPASS and SURMOUNT trials

The short version

Tirzepatide is given once a week by subcutaneous injection (under the skin). Clinical trials started participants at a low dose (2.5 mg per week) and gradually increased it over 20 weeks — a process called titration — to reduce nausea and other stomach side effects that occur when the drug is introduced too quickly. The maximum dose studied and approved is 15 mg once weekly.

The three maintenance doses used across the SURPASS and SURMOUNT trials were 5 mg, 10 mg, and 15 mg once weekly. Higher doses generally produced larger effects on blood sugar and body weight, but also somewhat higher rates of gastrointestinal side effects. This page describes the doses documented in the label and clinical-trial literature. It does not recommend a dose — that is a clinical decision.

Tirzepatide dosage and titration schedule from the label

Tirzepatide dosage was studied in the SURPASS and SURMOUNT programmes using a 20-week stepwise titration schedule before reaching maintenance doses. The schedule documented in the prescribing information and phase 3 protocols: 2.5 mg once weekly for weeks 1–4, increased to 5 mg for weeks 5–8, to 7.5 mg for weeks 9–12, to 10 mg for weeks 13–16, to 12.5 mg for weeks 17–20, and to the maximum dose of 15 mg from week 21 onward ^[16]. The 20-week escalation was designed to allow physiological adaptation and minimize gastrointestinal intolerance during dose increases, which is when adverse events are most frequent ^[12][14].

The three maintenance doses evaluated in the phase 3 programme were 5, 10, and 15 mg once weekly. The dose-response relationship was consistent across the SURPASS trials for HbA1c reduction and across the SURMOUNT trials for weight loss ^[9][4]. Participants who did not tolerate a given dose could remain at the previous step; trial protocols allowed staying at any intermediate dose (5, 7.5, 10, or 12.5 mg) as the maintenance dose if the maximum was not tolerated ^[4].

The only route studied in the approved programme is subcutaneous injection. The prescribing information covers specific injection technique, site rotation, and storage ^[16].

Tirzepatide dose and pharmacokinetics

Tirzepatide dose and pharmacokinetics are governed primarily by its fatty-diacid modification. The C20 diacid arm binds non-covalently to serum albumin, dramatically extending the otherwise short half-life of a 39-amino-acid peptide. The measured elimination half-life is approximately five days, which supports once-weekly dosing and produces relatively stable plasma concentrations between doses ^[1].

The gastric emptying delay that tirzepatide produces was characterized in a dedicated phase 1 pharmacokinetic study (Urva 2020), which found that tirzepatide delays gastric emptying transiently and to a degree similar to selective long-acting GLP-1 receptor agonists; the effect attenuates with continued exposure over weeks ^[24]. This gastric-emptying effect has clinical implications: it can alter the absorption of co-administered oral medications, including oral hormonal contraceptives, and requires modified pre-procedure fasting guidance due to the theoretical aspiration risk under anesthesia ^[23][16].

Clearance is primarily through peptide catabolism via proteolysis. The long half-life means full washout requires several weeks after the last dose, which is relevant for the weight regain data observed after discontinuation ^[28][29].

Tirzepatide side effects: what the dose-escalation data shows

Gastrointestinal adverse events are the dominant dose-related safety finding across the SURPASS and SURMOUNT programmes. Nausea, vomiting, diarrhea, constipation, and decreased appetite were the most frequently reported adverse events, occurring primarily during dose escalation periods and diminishing with stable dosing ^[1][3][4].

In SURMOUNT-1, the proportion of participants experiencing nausea ranged from approximately 22–31% across the three dose groups versus 11% with placebo. Vomiting was reported by approximately 6–18% versus 2% with placebo. Most events were mild to moderate ^[4].

A systematic review and meta-analysis of nine randomised trials (9,871 participants) examined pancreatitis and gallbladder or biliary disease specifically. Tirzepatide was not associated with a statistically significant increase in pancreatitis (relative risk 1.46, 95% CI 0.59–3.61), but was significantly associated with the composite of gallbladder or biliary disease (relative risk 1.97, 95% CI 1.14–3.42) versus controls ^[18].

A comparative efficacy and safety meta-analysis against dulaglutide found that discontinuation due to adverse events was approximately 32% higher with tirzepatide, driven predominantly by gastrointestinal effects ^[31]. The prescribing information documents these dose-related patterns and the titration schedule designed to minimize them ^[16].

For the full anecdotal safety profile and clinical safety signals, see Tirzepatide effects.

Half-life, dosing interval, and timing

The approximately five-day elimination half-life means tirzepatide accumulates slightly over several weeks of once-weekly dosing before reaching a pharmacokinetic steady state. The once-weekly subcutaneous injection can be administered on any day of the week, at any time of day, with or without food — the prescribing information specifies these practical administration details ^[16].

The long half-life also means that switching days is possible by administering the next dose no sooner than three days after the previous dose, after which the new injection day schedule can continue weekly. Subcutaneous injection sites include the thigh, abdomen, or upper arm, with rotation between sites recommended to manage injection site reactions ^[16].

For tirzepatide injection pharmacokinetics and the PK characterisation data in detail, see the dedicated injection page.